Authors:
JOSTING A
KATAY I
RUEFFER U
WINTER S
TESCH H
ENGERT A
DIEHL V
WICKRAMANAYAKE PD
Citation: A. Josting et al., FAVORABLE OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY HODGKINS-DISEASE TREATED WITH HIGH-DOSE CHEMOTHERAPY AND STEM-CELL RESCUE AT THE TIME OF MAXIMAL RESPONSE TO CONVENTIONAL SALVAGE THERAPY (DEXA-BEAM), Annals of oncology, 9(3), 1998, pp. 289-295
Authors:
WICKRAMANAYAKE PD
STEINMETZ HT
KATAY I
GLASMACHER A
STAIB P
DIEHL V
Citation: Pd. Wickramanayake et al., PHASE-II TRIAL OF IDARUBICIN, FLUDARABINE, ARA-C, AND FILGRASTIM FILGRASTIM (G-CSF) (IDA-FLAG) FOR TREATMENT OF POOR-PROGNOSIS ACUTE MYELOID-LEUKEMIA (AML), Blood, 86(10), 1995, pp. 3009-3009
Authors:
SCHEID C
FUCHS M
WINTER S
SCHULZ A
JOSTING A
KATAY I
DIEHL V
DIASWICKRAMANAYAKE P
Citation: C. Scheid et al., DIFFERENTIATION OF A CELL-LINE FROM A PATIENT WITH ACUTE MEGAKARYOBLASTIC LEUKEMIA AWL M7, Blood, 86(10), 1995, pp. 3100-3100
Authors:
WICKRAMANAVAKE PD
STEINMETZ HT
KATAY I
GLASMACHER A
NEUFANG A
STAIB P
SCHWONZEN M
DIEHL V
Citation: Pd. Wickramanavake et al., PHASE-II TRIAL OF IDARUBICIN, FLUDARABINE, CYTIDINE ARABINOSIDE (ARA-C), AND FILGRASTIM (G-CSF) (IDA-FLAG) FOR TREATMENT OF POOR-PROGNOSIS ACUTE MYELOID-LEUKEMIA (AML), Blood, 84(10), 1994, pp. 10000618-10000618